August 7th 2025
New findings confirm TearCare's long-term effectiveness for dry eye disease, showing significant patient improvements with minimal treatments over 2 years.
FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease
May 29th 2025Alcon’s dry eye candidate acoltremon 0.003% is a first-in-class thermoreceptor agonist, which stimulates corneal sensory nerves to increase natural tear production to treat the signs and symptoms of dry eye disease.
Read More
Optimizing the diagnosis and treatment of evaporative dry eye through meibomian gland management
January 27th 2025Alice T. Epitropoulos, MD, FACS, outlines her approach to managing evaporative dry eye. This includes diagnosing meibomian gland dysfunction, using thermal pulsation to clear gland blockages, and ensuring long-term results with advanced treatments and patient education.
Read More